Patents Assigned to Boehringer Ingelheim International GmbH
  • Publication number: 20190177420
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.
    Type: Application
    Filed: July 18, 2018
    Publication date: June 13, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Thomas B. Freeman, Gerald Henery Nabozny, Meera Ramanujam, Paul Scholl, Juergen Steffgen
  • Publication number: 20190169301
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: July 10, 2018
    Publication date: June 6, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • Patent number: 10308667
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 4, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Cédrickx Godbout, Thomas Trieselmann, Viktor Vintonyak
  • Patent number: 10307402
    Abstract: The present invention relates to compounds of general formula I, wherein the group R1, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: June 4, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Joerg P. Hehn, Christoph Hoenke, Elke Langkopf
  • Patent number: 10308414
    Abstract: Methods and systems for calculating a suitability indicator which corresponds to a suitability of a packaging system for packaging a substance, where a stability indicator which corresponds to a stability of the substance or of a component of the substance is determined as a function of at least one ambient condition, preferably the relative humidity and/or temperature of the environment of the substance, and the suitability indicator is calculated with at least one parameter relating to the ambient condition and with the stability indicator of the substance.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: June 4, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Eduard Balthes
  • Patent number: 10301313
    Abstract: The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: May 28, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Sieger, Dirk Kemmer, Peter Kohlbauer, Thomas Nicola, Martin Renz
  • Publication number: 20190144534
    Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: January 25, 2019
    Publication date: May 16, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Keith A. Canada, Katrina Mary Catron, Robert Copenhaver, Lee Edward Frego, Ernest Lee Raymond, Sanjaya Singh, Xiangyang Zhu
  • Patent number: 10287318
    Abstract: The invention relates to novel peptides, polypeptides or proteins which bind specifically to brain cells and/or to the spinal cord. The peptides, polypeptides, or proteins can be components of a viral capsid and can be used to lead a recombinant viral vector selectively to the brain and/or spinal cord after systemic administration to a subject and to ensure tissue-specific expression of one or more transgenes there. The invention also relates to a recombinant viral vector, preferably an AAV vector, which comprises a capsid containing at least one of the claimed peptides, polypeptides, or proteins and which comprises at least one transgene packaged in the capsid. Said viral vector can be used, in particular for the therapeutic treatment of a disease or disorder of the brain and/or spinal cord. The invention further relates to cells and pharmaceutical compositions that comprise the viral vector according to the invention.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: May 14, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jakob Körbelin, Stefan Michelfelder, Martin Trepel
  • Patent number: 10280133
    Abstract: The present invention relates to a process for the preparation of 4-aminobenzoamidine (4-AMBA) salts of general formula (I) preferably the salts thereof with hydrochloric or hydrobromic acid, particularly preferred the dichloride salt.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: May 7, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Weitong Dong, Christian Wolfgang Hemp, Xiangle Jin, Jun Lu, Ulrich Scholz, Shengmin Su, Wei Xu, Jinsong Yang
  • Patent number: 10280231
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 7, 2019
    Assignees: Boehringer Ingelheim International GmbH, MacroGenics, Inc.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • Patent number: 10272215
    Abstract: An inhalation training device and inhalation training system for practicing of an inhalation process of a patient. The inhalation training device has a that is housing attachable to and detachable from a mouthpiece of an inhaler designed to provide a drug to the patient and a microphone adapted to measure the airflow occurring in the mouthpiece of the inhaler during an inhalation process of the patient. The inhalation training system includes the inhalation training device, an inhaler and an electronic device configured for evaluation of a signal received from the inhalation training device and for visual and/or audio feedback to the patient.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: April 30, 2019
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patricia Adams, Marion Frank, Herbert Wachtel
  • Publication number: 20190112295
    Abstract: This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5 have meanings given in the description.
    Type: Application
    Filed: April 17, 2017
    Publication date: April 18, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta LESSEL, Janet Rachel NICHOLSON, Anton PEKCEC
  • Patent number: 10258753
    Abstract: An inhalation training system and a method for practicing of an inhalation process and a method of operating a portable communications device in this respect and to an information storage medium are improved. An air flow during inhalation is converted into an acoustic signal, especially a whistling tone. The acoustic signal is picked up by a microphone of a portable communications device, such as a smartphone, and is electronically evaluated. The inhalation training system has a mouthpiece and a converter apparatus for converting the air flow into the acoustic signal and in addition has a holding apparatus for especially detachable holding of the communications device.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: April 16, 2019
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patricia Adams, Marion Frank, Herbert Wachtel
  • Patent number: 10258637
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: April 16, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, Hans-Juergen Woerle
  • Patent number: 10252994
    Abstract: The present invention relates to a method for the synthesis of a halo olefin of formula (I) wherein Hal, R1, R2, R3, R4, X and Y are as defined herein, or a salt thereof.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: April 9, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Mai Thi Quynh Dang, Thomas Armin Hampel, Sandra Koch, Fredrik Lars Nordstrom, Jonathan Timothy Reeves, Carsten Reichel, Marvin Schoerer, Christian Stange, Ivan N. Volchkov, Li Zhong, Uwe Johannes Zimmermann
  • Patent number: 10253004
    Abstract: The present invention relates to compounds of formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: April 9, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner, Stefan Peters
  • Patent number: 10251840
    Abstract: The invention relates to an improved method of manufacturing substantially spherical/ball-shaped tartaric acid starter pellets which are suitable for preparing active substance-containing medicament formulations, as well as the pellets as such that may be obtained in this way, and their use as starting material for the preparation of active substance-containing medicament formulations.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: April 9, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Johann-Georg Maier
  • Patent number: 10246467
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: April 2, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Joachim Broeker, Annika Gille, Andreas Gollner, Manuel Henry, Nina Kerres, Harald Weinstabl
  • Patent number: 10238633
    Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: March 26, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Florian Binder, Matthias Grauert, Marc Grundl, Peter Wilhelm Haebel, Thorsten Oost, Alexander Pautsch, Stefan Peters, Viktor Vintonyak
  • Patent number: 10232134
    Abstract: An inhalation training device and inhalation training system for practicing of an inhalation process of a patient. The inhalation training device has a that is housing attachable to and detachable from a mouthpiece of an inhaler designed to provide a drug to the patient and a microphone adapted to measure the airflow occurring in the mouthpiece of the inhaler during an inhalation process of the patient. The inhalation training system includes the inhalation training device, an inhaler and an electronic device configured for evaluation of a signal received from the inhalation training device and for visual and/or audio feedback to the patient.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: March 19, 2019
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patricia Adams, Marion Frank, Herbert Wachtel